Story perspectives

Medicare Coverage to Boost Launch of Orforglipron Drug

1/31/2026

Summary

Ricks Promotes Orforglipron

Eli Lilly Chief Executive Officer Dave Ricks said in a CNBC interview that Medicare's obesity-drug coverage could boost orforglipron's launch.
He noted Medicare coverage would begin immediately after the pill's launch, enhancing its market potential.
Ricks noted many patients pay out of pocket for Wegovy, Novo Nordisk's GLP-1, with strong initial adoption.
He expressed confidence in orforglipron, with a full launch planned for Q2 to align with Medicare's new coverage.

Summary

Lilly Invests Billions

Eli Lilly and Company plans to invest over $3.5 billion in a Lehigh Valley, Pennsylvania plant to produce next-generation obesity treatments, including retatrutide.
The project marks Lilly's fourth manufacturing investment since February 2025, aligning with a broader commitment of at least $27 billion to bolster domestic production.
Construction begins this year.
The plant will create about 850 permanent jobs and partner with local universities to support workforce development.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act, signed into law by President George W. Bush on December 8, 2003, marked a significant expansion of Medicare, introducing Part D for prescription drug coverage, which began on January 1, 2006. By 2006, over 39 million beneficiaries were enrolled, prompting pharmaceutical companies like Eli Lilly to invest strategically in new treatments, reflecting a shift towards enhanced healthcare access and domestic production.

1 of 3

Ricks Promotes Orforglipron

Eli Lilly Chief Executive Officer Dave Ricks said in a CNBC interview that Medicare's obesity-drug coverage could boost orforglipron's launch.
He noted Medicare coverage would begin immediately after the pill's launch, enhancing its market potential.
Ricks noted many patients pay out of pocket for Wegovy, Novo Nordisk's GLP-1, with strong initial adoption.
He expressed confidence in orforglipron, with a full launch planned for Q2 to align with Medicare's new coverage.

1 / 3